Tivantinib, a c-Met TKI which inhibits tumor growth in mice [12], is currently in Phase III clinical trials and has been shown to increase PFS from 9.7 to 16.1 weeks when given in combination with erlotinib [13], [14]. The gene discussed is MET; the disease is neoplasm.